RxDoctor Payments Data

Alison McCann

Nurse Practitioner · Erie, PANPI 1538612726

Payments from drug & device makers

$4,962in general payments, 2019–2025

Across 170 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$536
  • Johnson & Johnson$503
  • AstraZeneca$502
  • Merck$468
  • Inari Medical, Inc.$381
  • Novartis$306
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,962 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,633
Medicare patients
91
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan152$114,811
XareltoRivaroxaban90$56,327
JardianceEmpagliflozin22$30,005
FarxigaDapagliflozin Propanediol28$20,729
EliquisApixaban27$19,149
Repatha SureclickEvolocumab16$8,664
Metoprolol Succinate62$1,168
Bumetanide34$958
Gabapentin17$470
Atorvastatin Calcium50$441
Ranolazine ErRanolazine12$399
Potassium Chloride24$390
Furosemide64$339
Carvedilol24$267
Pantoprazole Sodium35$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$306$114,811152 claims
Johnson & JohnsonXarelto$503$56,32790 claims
Boehringer IngelheimJardiance$91$30,00522 claims
AstraZenecaFarxiga$502$20,72928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →